Form 4: Protagonist Therapeutics Director Sells Shares Under 10b5-1 Plan

Protagonist Therapeutics Director William D. Waddill reported transactions involving the sale of common stock and the exercise of stock options, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Director William D. Waddill engaged in transactions involving Protagonist Therapeutics, Inc. (PTGX) common stock.
• On June 23, 2026, 9,000 shares of common stock were acquired at a price of $16.54 per share, totaling $148,860.
• On the same date, 9,000 shares of common stock were disposed of at a weighted average price of $117.94 per share, with individual sales ranging from $117.00 to $119.07.
• Following these transactions, Waddill beneficially owns 7,825 shares of common stock.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on February 27, 2026.
• Stock options held by Waddill are fully vested.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a director, despite the use of a 10b5-1 plan which mitigates some concerns about opportunistic trading.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impactful sales.
• The stock options exercised are fully vested, suggesting a mature equity award.

Negatives

• A significant number of shares were sold by a director, which could be perceived negatively by the market.
• The sale of 9,000 shares at a weighted average price of $117.94 represents a substantial disposition of holdings.

Risks

• Potential for negative market perception due to insider selling, even if executed under a 10b5-1 plan.
• Future sales under the 10b5-1 plan could further impact share price if not balanced by buying interest.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future company performance. It solely reports past transactions.

Management Comments

• The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026.
• The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07.
• Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
• These stock options are fully vested.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a 10b5-1 plan by a director of Protagonist Therapeutics, Inc. is a common practice to facilitate stock sales while adhering to insider trading regulations, particularly in the biotechnology sector where stock price can be volatile based on clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a director as a signal of reduced confidence or a need for liquidity, potentially impacting share price.
• Employees: May observe insider selling and consider its implications for company prospects.
• Management: The use of a 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider trading.

Next Steps

• The reporting person may continue to execute transactions under the existing 10b5-1 plan.
• The company may issue further updates on insider transactions as they occur.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established 10b5-1 plan. While the sale of a significant number of shares by a director could be a short-term negative catalyst, the structured nature of the sale under a plan suggests it's not necessarily a reflection of negative fundamental outlook. Investors should monitor the company's core business developments rather than solely focusing on this insider transaction for investment decisions.

Keywords

Form 4, Insider Trading, Protagonist Therapeutics, PTGX, William D. Waddill, Stock Options, 10b5-1 Plan, Beneficial Ownership, Securities Exchange Act